Clinical Trial: Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer

U.S., April 29 -- ClinicalTrials.gov registry received information related to the study (NCT07553780) titled 'Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer' on March 11.

Brief Summary: This prospective, multicenter study aims to evaluate the clinical utility of serial PSMA PET for therapy monitoring in patients with newly diagnosed clinically significant prostate cancer.

Clinically significant prostate cancer is defined as Gleason score >=7.Patients will undergo baseline PSMA PET/CT prior to any treatment. A second PSMA PET/CT will be performed either at PSA recurrence (PSA rise >=2 ng/mL above nadir after radiotherapy or biochemical progression per PCWG3 criteria) or at a fixed time window of 12-24 mont...